Abstract 3655
Background
Patients with NSCLC characterized by ALK rearrangements may benefit from ALK TKI therapies. Although ALK TKIs have shown improved efficacy relative to conventional chemotherapy, the prognosis for patients with ALK+ NSCLC remains suboptimal. The present study uses real-world evidence to examine progression-free survival (PFS) among patients with ALK+ NSCLC treated with an ALK TKI.
Methods
Patients with advanced ALK+ NSCLC diagnosed and treated with an ALK TKI in 2011-2017 were identified from the Flatiron Health Electronic Health Record (EHR)-derived database. Real-world PFS (rwPFS) was estimated as the time from treatment line start to progression or death, where progression was abstracted from clinician notes and radiology/pathology reports by trained medical reviewers. Analyses examined rwPFS following the patient’s first line containing ALK TKI. For patients who received crizotinib as their first TKI followed by a second ALK TKI, a similar analysis examined rwPFS following their second ALK TKI line. Data were censored at end of follow-up for patients without progression or death. The median and 95% confidence interval (CI) of rwPFS following first and second ALK TKI were obtained from Kaplan-Meier methods.
Results
Of 409 ALK TKI-treated patients with advanced ALK+ NSCLC, mean age was 60.4 years and 51.6% were female. Most patients (n = 379; 92.7%) received crizotinib as their first ALK TKI; of these, 180 (47.5%) were later treated with a second ALK TKI (e.g. ceritinib, alectinib). Median (95% CI) rwPFS was 7.5 (6.6-8.6) months following first ALK TKI; and 6.4 (5.2-8.2) months following second ALK TKI post-crizotinib (including 6.3 [4.3-8.4] months for ceritinib (n = 99) and 7.6 [5.2-13.6] months for alectinib (n = 64)).
Conclusions
In this real-world analysis of patients with advanced ALK+ NSCLC treated with earlier approved ALK TKIs, rwPFS remains short, indicating a clear need for more effective treatments of ALK+ NSCLC.
Clinical trial identification
Legal entity responsible for the study
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Funding
Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Editorial Acknowledgement
Writer: Beth Nordstrom; company: Evidera.
Disclosure
M. Jahanzeb: Research grant: Lilly, Boehringer Ingelheim, Callisto; Research grant and consultant: Ipsen, Roche/Genentech, Pfizer. H.M. Lin: Employment, stock and other ownership: Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. X. Pan, A. Desai: Employment: Takeda. B.L. Nordstrom: Employment: Evidera. All other authors have declared no conflicts of interest.
Resources from the same session
4679 - Correlative analyses of serum biomarkers and efficacy outcomes in the randomized phase 2 trial of lenvatinib (LEN), everolimus (EVE), or LEN+EVE in patients with metastatic renal cell carcinoma
Presenter: Chung-Han Lee
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5379 - End-to-end learning to predict survival in patients with gastric cancer using convolutional neural networks
Presenter: Armin Meier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5394 - Detection of Targetable Kinase Fusions in 7260 patients in an integrated Cancer System
Presenter: Ankur Parikh
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5884 - Clinical and analytical validation of an FDA approved comprehensive genomic profiling (CGP) assay incorporating multiple companion diagnostics for targeted and immunotherapies
Presenter: Yali Li
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5912 - SET overexpression promotes colorectal cancer progression and determines poor outcome in patients with localized disease.
Presenter: Blanca Torrejón
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
1168 - The functional MDM4 genetic variant in advanced lung adenocarcinoma patients treated with EGFR-TKIs
Presenter: Nasha Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3071 - PD-L1 expression on pre-treatment circulating tumour cells, but not serum VEGF, is predictive of response to pembrolizumab in melanoma
Presenter: Muhammad Khattak
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4062 - Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer
Presenter: Yu-Zhen Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4801 - A diagnostic model for hepatitis B virus-related hepatocellular carcinoma in China: a large-scale, multi-center study
Presenter: Tian Yang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
4874 - Dissecting Gastric Cancer biology and how and when to use immunotherapy
Presenter: Meghna Das Thakur
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract